Physician profile
Vanessa Marin
NPI 1124176037
$1,223.10
in general payments reported to CMS, 2019-2025
12 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.03 · 2020: $14.44 · 2022: $93.01 · 2023: $480 · 2024: $140 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $893 · Travel and Lodging: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $892.58 |
| Travel and Lodging | $182.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Imaging Healthcare North America, INC. | $313.03 | 2025 | N/A, Pet, Umi |
| Boston Scientific Corporation | $275.98 | 2023-2024 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $148.04 | 2020-2025 | |
| Pfizer INC. | $133.27 | 2019-2025 | |
| Amgen INC. | $98.99 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $97.72 | 2022-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $38.78 | 2024-2025 | Lokelma, Wainua |
| E.R. Squibb & Sons, L.L.C. | $38.04 | 2022-2023 | Eliquis |
| Siemens Medical Solutions USA, INC. | $31.70 | 2025 | Biograph Horizon-3r |
| Bayer Healthcare Pharmaceuticals INC. | $19.92 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $16.12 | 2023 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Marin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.